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Hepatocellular carcinoma (HCC) is one of the most malignant human tumours because of its high incidence of metastasis. The
mechanisms underlying the metastasis of HCC, however, remain poorly understood. In this study, we performed cDNA microarray
analysis to profile gene expression patterns in two subtypes of HCC, solitary large HCC (SLHCC) and nodular HCC (NHCC), which
differ significantly in the incidence of metastasis. Among 668 genes that were differentially expressed, we focused on RhoC, whose
expression was significantly decreased in SLHCC compared to NHCC. The expression of RhoC in HCC and pericarcinomatous liver
tissues (PCLT) was analysed at both the mRNA and protein levels by reverse transcription–polymerase chain reaction (RT–PCR)
and Western blotting. In addition, immunohistochemistry was also performed on 94 cases of HCC with follow-up information.
Collectively, our data indicate that the expression of RhoC significantly increased in HCC compared to PCLT; extrahepatic metastatic
lesions expressed significantly higher levels of RhoC than the corresponding intrahepatic HCC tissues. There is a highly significant
correlation of the RhoC expression levels with tumour vein invasion, number of tumour nodes and the status of differentiation.
Significantly, the HCC patients with RhoC-positive expression had shorter survival than those with RhoC-negative expression.
Together, our findings suggest a strong correlation between the expression of RhoC and HCC metastasis, implicating RhoC as a
potential prognosis marker and therapeutic target for HCC.
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Hepatocellular carcinoma (HCC) is one of the most common
malignancies in Asia and Africa (Murray and Lopez, 1997;
Akriviadis et al, 1998), especially in China. It is responsible for
approximately one million deaths each year, predominantly in the
developing countries (Schafer and Sorrell, 1999). During the past
decade, hepatic resection for HCC has evolved into a safe
procedure with low operative mortality (Makuuchi et al, 1998;
Fan et al, 1999). However, the long-term survival remains
unsatisfactory because of a high incidence of recurrence and
metastasis after hepatic resection, with a 5-year actuarial
recurrence rate of 75–100% reported in the literature (Poon et al,
2000). Most recurrence was attributed to invasion and metastasis
of HCC, so the elucidation of prognostic factors reflecting invasion
and metastasis not only provides guidance in the choice of
treatments but also allows better prognostic counselling.
It has been generally accepted that the invasive and metastatic
potential of HCC was mostly attributed to the individual
clinicopathological and biological characteristics. The diversity of
biological characteristics determines the different invasive and
metastatic potential of HCC (Okuda, 1997). Based on this diversity,
in our institute, HCC was distinct phenotypically to: solitary large
hepatocellular carcinoma (SLHCC, diameter 45cm, and one
node), which often grows expansively with capsule or pseudocap-
sule formation and has a favourable biological behaviour, nodular
hepatocellular carcinoma (NHCC, node number X2) and small
hepatocellular carcinoma (SHCC, diameter p5cm). Our previous
study found that SLHCC, although it shared large size, had long-
term survival after hepatic resection compared to NHCC, which
implied different invasive and metastatic potential between SLHCC
and NHCC. However, further investigation of different invasive
and metastatic potential between them was anticipated.
RhoC-GTPase, a member of the Ras superfamily of small
guanosine triphosphatases (GTPases), shuttles between inactive
GDP- and active GTP-bound form and exhibits intrinsic GTPase
activities. Activation of Rho protein leads to the assembly of the
actin–myosin contractile filaments into focal adhesion complexes
that lead to cell polarity and facilitate motility (Nobes and Hall,
1995; Kimura et al, 1996; Leung et al, 1996). Recently, emerging
data suggest that RhoC gene may have a potential role in
carcinogenesis and metastasis of tumour cells (Itoh et al, 1999;
Clark et al, 2000). The expression level of RhoC in metastatic
region of pancreatic cancer has been previously reported to be
higher than primary lesion (Suwa et al, 1998). In addition, a
genomic-wide analysis of gene expression revealed that RhoC gene
was involved in vascular invasiveness of HCC (Okabe et al, 2001).
To gain a better understanding of the difference in invasion and
metastasis between SLHCC and NHCC, we employed cDNA
microarray technology to profile gene-expression patterns in these
two subtypes of HCC. Among 668 genes that were differentially
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further study because of its potential association with tumour
metastasis.
MATERIALS AND METHODS
Tissue specimens
The study protocol was approved by the Ethics Committee of the
Central South University. Fresh samples of HCC tissues and
pericarcinomatous liver tissues (PCLT, 1cm away from the
carcinoma) were obtained from 25 (22 male and 3 female) patients
with hepatocellular carcinoma who underwent hepatoectomy at
Xiangya Hospital of Central South University (CSU). The speci-
mens were immediately flash frozen in liquid nitrogen and stored
at  801C for RT–PCR and Western blotting. The median age of the
patients was 53 years, ranging from 28 to 73 years. All specimens
obtained from hepatic resection were confirmed by pathological
examination and clinicopathological parameters, such as tumour
diameter, number of tumour node, tumour capsule, histopatholo-
gical classification, vein invasion and extrahepatic metastatic
lesion. On this basis, the total number of cases could be divided
into three groups (SLHCC, n¼7; NHCC, n¼15; SHCC, n¼3).
RNA isolation
Total RNA was extracted from frozen tissue specimens (30–
100mg) using TRIZOL (GIBCO BRL, Gaithersburg, USA) reagent,
according to the instructions provided by the manufacturer. The
quality was checked in 1% agarose gels and the concentration was
measured using an ultraviolet Spectrophotometer (Biochrom Ltd,
Cambridge, England) (Suwa et al, 1998). The UV wavelength was
adjusted at 260nm.
cDNA microarray
cDNA microarray was carried out on 22 cases (7 SLHCC and 15
NHCC) of HCC specimens. Examination of quality and quantity
for individual RNA was performed, and all RNA samples were
eligible. As we investigated the differentially expressed genes
between the SLHCC group and NHCC group, the individual RNA
specimens in the same group were mixed equally to obtain 30mg
total RNA, which was reversely transcribed using reverse
transcriptase (GIBCO BRL, Gaithersburg, USA). The mixed RNA
samples from SLHCC were labelled with Cy-5 and those from
NHCC were labelled with Cy-3. After incubation at 421C for 2h, the
reactions of the two samples (one with Cy-3 and other with Cy-5)
were mixed and purified by using a filtration spin column
(Promega, Madison, USA). The whole volume of the purified
probe was denatured at 951C for 2min and was applied to the
cDNA microarray slide containing 8464 genes, which was provided
by United Gene Holdings (Biostar Genechip Inc., Shanghai,
China). The control spots of non-human origin in cDNA
microarray slide include the U2 RNA gene, Hepatitis C Virus coat
protein gene and spotting solution alone without DNA. After
hybridisation at 421C for 18h, the slide was washed for 10min each
in solutions of 2 SCC and 0.2% SDS, 0.1% SCC and 0.2% SDS
and 0.1% SCC. Finally, the cDNA microarray slide was scanned
with a Scan Array 4000 Standard Biochip Scanning System
(Packard Biochip Technologies, VA, USA) at two wavelengths to
detect the emission of both Cy5 and Cy3. The acquired image was
analysed using ImaGene 3.0 software (Bio Discovery, Los Angeles,
USA). The intensities of each spot at the two wavelengths represent
the quantity of Cy5 and Cy3, respectively, hybridised to each spot.
Ratios of Cy5 to Cy3 were computed for each location. The overall
intensities were normalised with a correction coefficient obtained
using the ratio of 64 housekeeping genes. Genes were identified as
differentially expressed if the absolute value of the natural
logarithm of the ratios was 40.69. To minimise artefacts arising
from low expression values, only genes with raw intensity values
for both Cy5 and Cy3 of 4800 counts were selected for differential
analysis (Li et al, 2002).
Reverse transcription and polymerase chain reaction
(RT–PCR)
Total RNA (2mg) was reversely transcribed in a final 25ml reaction
volume at 371C for 1h by using 200U M-MULV reverse
transcriptase (Promega, Madison, USA). PCR amplification was
performed in a final volume of 50ml containing 5ml first-strand
cDNA solution, 2U Taq polymerase (Sangon, Shanghai, China),
5ml1 0 PCR reaction buffer, 10mM of dNTP (Sangon, Shanghai,
China) and 10pmol of each 30 and 50 sequence-specific oligonu-
cleotide primer (Sangon, Shanghai, China) for RhoC and b2-
microglobulin gene (positive control). The primer sequences were
as follows: human RhoC, 50-TCCTCATCGTCTTCAGCAAG-30
(forward), 50-CTGCAATCCGAAAGAAGCTG-30 (reverse); and hu-
man b2-microglobulin, 50-ACCCCCACTGAAAAAGATGA-30 (for-
ward), 50-ATCTTCAAACCTCCATGATG-30 (reverse). The
amplification was performed on a DNA Thermal cycler (Perkin-
Elmer, Shelton, USA) with an initial denaturation at 941C for
3min, followed by 32 cycles of denaturation at 941C for 40s,
annealing at 561C for 30s and extension at 721C for 1min, and a
final extension at 721C for 10min. PCR products were electro-
phoresed on 1.7% agarose gels; the bands representing amplified
products were visualised using ethidium bromide during the
exposure to a UV transilluminator. The density of the bands on the
gel was quantified by densitometric analysis. RhoC gene expres-
sion was presented by the relative intensity of the PCR product
bands from target sequences to that from the b2-microglobulin
gene (Suwa et al, 1998).
SDS–PAGE and Western blotting
Tissues from HCC and PCLT were lysed in a lysis buffer; 20mM
Tris-HCl pH¼7.4, 10mM NaCl, 1mM EDTA pH¼8.0, 1mM MgCl2,
1% NP-40, 0.1% SDS, 0.01% PMSF (Sigma, St Louis, MO, USA) and
protease-inhibitor (Promega, Madison, USA). The lysates were
centrifuged at 13000g for 20min at 41C, and the supernatants were
stored at  801C. Extracts equivalent to 100mg of total protein were
separated by stacking gel (3.5%) and SDS–PAGE (12.5%)
separating gel with Tris-glycine system at 200V for 1h. Blotting
was performed to polyvinylidene fluoride membrane (Sigma, St
Louis, MO, USA) at 100V for 1h in a tank of transfer buffer
(48mM Tris-HCl, 192mM glycine, 20% methanol pH¼8.4). The
membranes were blocked in 4% nonfat dry milk in PBS containing
0.1% Tween-20 for 1h at room temperature. Then, the membranes
were incubated with primary antibody (goat anti-human RhoC
polyclonal antibody, Santa Cruz, CA, USA, diluted at 1:500) for 1h
at 371C. After washing, the membranes were incubated with a
1:1000 dilution of horseradish peroxidase-linked rabbit anti-goat
antibody (Santa Cruz, CA, USA) for 30min at 371C. Then the
membranes were washed and treated with Western blotting
luminal reagent (Santa Cruz, CA, USA) to visualise the bands;
the results were obtained on Kodak film and quantified by
densitometry (Beckman, South Pasadena, Canada) (Abraham et al,
2001).
Immunohistochemistry
A total of 94 HCC specimens, including the 25 cases of HCC fresh
specimens (used for RT–PCR and Western blotting), were
evaluated for immunohistochemistry. All the specimens were
collected from Xiangya Hospital of Central South University
between 1994 and 2002. Follow-up data were obtained following
operation for all patients; the end point of follow-up was set at the
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ypatient’s death. In brief, tissue sections of 4mm thick were cut and
baked at 601C for 2h, deparaffinised in xylene and rehydrated
through graded ethanol. Next, 3% hydrogen peroxide was applied
to block the endogenous peroxidases for 20min and sections were
subjected to heat-induced antigen retrieval in 0.01 M citrate buffer
(pH¼6.0). The sections were incubated with normal goat serum to
reduce nonspecific binding. Then, they were incubated at 371C for
1h with specific antibodies (goat anti-human RhoC polyclonal
antibody, Santa Cruz, CA, USA) used at a 1:100 dilution. The
second antibody was applied for 45min at 371C. The streptavidin–
biotin–peroxidase complex (SABC) tertiary system (Boster,
Wuhan, China) was used according to the manufacturer’s
instruction for 20min at room temperature. The tissues were
visualised by applying 3,3-diaminobenzidine tetrahydrochloride
(DAB) for 3min. Sections were counterstained using haematox-
ylin, dehydrated through gradient alcohols and mounted for
viewing. Negative controls were carried out by omitting the
primary antibody, whereas RhoC overexpression confirmed by
Western blotting was used as positive controls. The intensity of
cytoplasmic staining was scored as 0 to 3þ by comparison to the
positive controls. The scoring system has been previously validated
(Kleer et al, 2002). Diffuse, moderate to strong cytoplasmic
staining characterised RhoC-positive expression (scores 2þ and
3þ). RhoC-negative expressions were devoid of any cytoplasmic
staining or contained faint, equivocal staining (scores 0 and 1þ,
Figure 1)
Statistical analysis
Statistical analysis was performed using the SPSS (version 11.0,
Chicago, IL, USA). The Fisher’s exact test was performed to access
differences in clinicopathological parameters between SLHCC and
NHCC. Spearman’s correlation coefficient was used to examine the
relationship between expression levels of RhoC mRNA and
protein. The nonparametric Mann–Whitney test was monitored
to evaluate the differences in the expression of RhoC between
groups, and also to analyse the correlation between the expression
of RhoC and clinicopathological variables. Postoperative survival
was analysed by the log-rank test. Differences were considered
significant when Po0.05.
RESULTS
Clinical and pathological characterisation of SLHCC and
NHCC
According to the criteria described in the introduction, there were
seven cases of SLHCC and 15 cases of NHCC among the total 25
cases of HCC studied. Most of the SLHCC cases were differentiated
at I–II (five out of seven, 71%), whereas considerably fewer cases
of NHCC (2 out of 15, 13%) exhibited the same level of
differentiation. In addition, there was a substantial difference in
tumour vein invasion with a significantly higher percent in NHCC
than in SLHCC (one out of seven, 14% SLHCC vs 11 out of 15, 73%
NHCC). There were five cases of SLHCC, but only three cases of
NHCC, which exhibited capsulation (5 out of 7, 71% SLHCC vs 12
out of 15, 20% NHCC) also. The distribution of sex, liver cirrhosis
in each group showed no significant differences (Table 1).
Evaluation of invasiveness score for HCC
Invasiveness score (IS) was applied to evaluate the invasive and
metastatic abilities of SLHCC and NHCC (El-Assal et al, 1997).
Three cases of SLHCC (three out of seven) and three cases of
NHCC (three out of 15) scored ISp1 (low invasive); three cases of
SLHCC (three out of seven) and five cases NHCC (five out of 15)
scored 2pISp4 (moderate invasive); and one case of SLHCC (one
out of seven) and seven cases of NHCC (seven out of 15) scored
ISX5 (high invasive). Collectively, the SLHCC group showed lower
IS scores than the NHCC group (P¼0.02), suggesting that SLHCC
is less invasive than NHCC.
Figure 1 (A) Typical staining for positive cytoplastic RhoC expression in
an HCC (original magnification  400). (B) Typical staining for negative
cytoplastic RhoC expression in an HCC (original magnification  400).
Table 1 Clinicopathological differences between SLHCC and NHCC
Variables SLHCC (n) NHCC (n) Fisher’s test
Sex
Male 6 14 P¼1.00
Female 1 1
Liver cirrhosis
Present 5 6 P¼0.36
Absent 2 9
Cell differentiation
I–II 5 2 P¼0.01
III–IV 2 13
Capsule formation
Present 5 3 P¼0.02
Absent 2 12
Vein invasion
Present 1 11 P¼0.02
Absent 6 4
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The distinct phenotypes displayed by SLHCC and NHCC implicate
differences in biology. To gain a better understanding of the
differences between SLHCC and NHCC, we made an attempt to
profile gene expression patterns in these two types of HCC using
cDNA microarray. By setting the threshold value of 2 (upregula-
tion) and 0.5 (downregulation) for assessing the difference in the
expression level between SLHCC and NHCC, 668 out of 8464
human genes (cDNA microarray, Biostar Genechip Inc., Shanghai,
China) were differentially expressed (355 upregulated and 313
downregulated genes). The altered genes clustered into different
subsets of cellular genes whose products are implicated in
biological activities generally consistent with the physiology and
pathology of SLHCC and NHCC. A partial list of the genes
differentially expressed is shown in Table 2. Complete information
of the cDNA microarray can be accessed through our website.
Collectively, the array data provide a genome-wide view of
differences in gene expression between SLHCC and NHCC. Of
particular interest among 668 genes that were differentially
expressed is the RhoC gene, whose expression is higher in highly
invasive NHCC than in less invasive SLHCC since RhoC expression
has been implicated in tumour metastasis. We therefore decided to
validate the array data by assessing the expression of RhoC at the
level of message RNA and protein in the HCC samples.
Expression of RhoC mRNA and protein
The expressions of RhoC mRNA and protein were detected in all
HCC tissues and PCLT. However, the levels of both RhoC mRNA
and protein are significantly higher in HCC tissues than in PCLT
(P¼0.001). Significantly, we detected substantially higher levels of
both RhoC mRNA and protein in extrahepatic HCC tissues than
those in intrahepatic HCC tissues (P¼0.009 and 0.002, Figures 2
and 3). Statistical analyses revealed a strongly positive correlation
(r¼0.735, Po0.001, Figure 4).
Correlation between RhoC expression levels and
clinicopathological parameters of HCC
The distribution pattern of RhoC was further analysed by dividing
the expression levels of RhoC mRNA and protein in subgroups
according to the clinicopathological parameters. Interestingly,
the RhoC mRNA and protein expression levels in HCC with
multinodes were significantly higher than those with one node
(P¼0.011 and 0.015). Furthermore, increased RhoC expression
strongly correlates with vein invasion (P¼0.006 and 0.030). A
significant difference in RhoC expression was also evident between
HCC with poor differentiation and those with well differentiation
(P¼0.004 and 0.002). There were no significant associations
between expression of RhoC gene and other clinicopathological
parameters such as sex, HBV infection, liver cirrhosis, tumour size
and capsular condition (Table 3).
Table 2 Parts of genes differentially expressed between SLHCC and NHCC
GeneBank ID Gene name Function Ratio (Cy5/Cy3)
NM_031934 Homo sapiens RAB34, member RAS oncogene family (RAB34), mRNA Cellular skeleton and
movement
0.224
NM_003177 Homo sapiens spleen tyrosine kinase (SYK), mRNA Signal transduction 0.240
NM_014624 Homo sapiens S100 calcium-binding protein A6 (calcyclin) (S100A6), mRNA Signal transduction 0.345
NM_022807 Homo sapiens small nuclear ribonucleoprotein polypeptide N (SNRPN), transcript variant 4,
mRNA
Growth and development 0.389
NM_001168 Homo sapiens baculoviral IAP repeat-containing 5 (survivin) (BIRC5), mRNA Cellular apoptosis 0.441
NM_175744 Homo sapiens ras homologue gene family, member C (ARHC), mRNA Cellular skeleton and
movement
0.463
NM_002530 Homo sapiens neurotrophic tyrosine kinase, receptor, type 3 (NTRK3), mRNA Growth and development 0.464
NM_001912 Homo sapiens cathepsin L (CTSL), mRNA Matrix degrade 0.477
NM_000210 Homo sapiens integrin, alpha 6 (ITGA6), mRNA Matrix degrade 0.493
NM_004394 Homo sapiens death-associated protein (DAP), mRNA Cellular apoptosis 2.014
NM_001901 Homo sapiens connective tissue growth factor (CTGF), mRNA Growth and development 2.026
NM_003445 Homo sapiens zinc finger protein 155 (pHZ-96) (ZNF155), mRNA Signal transduction 2.095
NM_000389 Homo sapiens cyclin-dependent kinase inhibitor 1A (p21, Cip1) (CDKN1A), mRNA Cellular apoptosis 2.292
NM_017675 Homo sapiens protocadherin LKC (PC-LKC), mRNA Matrix degrade 2.358
AF220656 Homo sapiens apoptosis-associated nuclear protein PHLDA1 (PHLDA1) mRNA, partial cds Cellular apoptosis 2.388
NM_001880 Homo sapiens activating transcription factor 2 (ATF2), mRNA Cellular apoptosis 3.090
NM_001257 Homo sapiens cadherin 13, H-cadherin (heart) (CDH13), mRNA Matrix degrade 4.60
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Figure 2 Detection of RhoC mRNA by RT–PCR. (A) PCR products
were visualised by ethidium bromide staining. Eight selected samples from
each group are shown: RhoC (181bp); b-MG (120bp); EHML:
extrahepatic metastatic lesions; HCC: hepatocellular carcinoma tissues;
PCLT: pericarcinomatous liver tissues. (B) The Mann–Whitney test was
performed to compare the mRNA expression of RhoC between different
groups; EHML showed a significantly higher mRNA expression level than
HCC and the same between HCC and PCLT.
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Kaplan–Meier survival curves for patients with HCC, categorised
according to RhoC expression, are shown in Figure 5. The mean
survival of patients with RhoC-positive expression, which was
determined by immunohistochemical staining (Figure 5), was
significantly lower (356 days) than that of patients with RhoC-
negative expression (579 days, P¼0.0031), indicative of a positive
correlation of RhoC expression with poor prognosis.
DISCUSSION
Classification and prognosis of HCC has been traditionally based
on the size of HCC; the large HCC is often considered as
advance and unresectable. However, we have observed that there
is one type of HCC, which is large in size but exhibits a lower
invasive and metastatic potential. This type of HCC typically has
just single node and we defined them SLHCC. On the contrary,
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Figure 3 Western analysis of RhoC protein. (A) The protein expression
levels were obtained on Kodak films and were quantified by densitometry.
A total of 10 selected samples were shown. (B) The Mann–Whitney test
showed significant differences between EHML and HCC, and also between
HCC and PCLT.
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Figure 4 Correlation between mRNA and protein expression levels of
RhoC in HCC was evaluated by Spearman’s correlation coefficient. RhoC
Protein levels were directly correlated with the levels of RhoC mRNA in
HCC with adjusted rs¼0.735, and two-tailed probability, Po0.001.
Table 3 Relationship between expression level of RhoC and clinico-
pathological parameters
P-value
Variables No. of patients RhoC mRNA RhoC protein
Sex
Male 22 0.675 0.452
Female 3
Liver cirrhosis
Present 14 0.584 0.622
Absent 11
Capsule formation
Present 13 0.785 0.744
Absent 12
Tumour node
X2 15 0.011 0.015
o21 0
Cell differentiation
I–II 9 0.004 0.002
III–IV 16
Vein invasion
Present 13 0.006 0.030
Absent 12
Extrahepatic metastasis
Present 5 0.103 0.077
Absent 20
Tumour size (cm)
45 18 0.287 0.904
p57
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Figure 5 Kaplan–Meier survival curves for RhoC-positive expression
group (n¼58) and RhoC-negative expression group (n¼36) based on the
results of immunohistochemistry. HCC patients with RhoC-positive
expression revealed a significantly poor prognosis than those with RhoC-
negative expression (log-rank test, P¼0.0031).
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often occur early despite their small size. This type of HCC,
however, has usually more than one node. These observations of
ours are consistent with the sixth TNM classification for HCC
revised by UICC that the number of nodes, but not size of HCC,
is the crucial factor for classification and prognosis of HCC
(Poon and Fan, 2003). We routinely divide HCC, based on the
distinct phenotype, into: SLHCC (diameter 45cm, only one
node), NHCC (node number X2) and SHCC (diameter p5cm).
Our clinical data indicate that NHCC displays a significantly
greater potency in invasion and metastasis than SLHCC does. In
keeping with the notion that cell differentiation status and vein
invasion highly correlate with the invasion and metastasis of
HCC (Liver Cancer Study Group of Japan, 1990; Farinati et al,
2000; Ohkubo et al, 2000; Utsunomiya et al, 2000), we found
that SLHCC is generally better differentiated and has less vein
invasion than NHCC. SLHCC is also prone to formulate
capsulation. Together with the IS, our data indicate that NHCC
in general has a greater propensity to undergo metastasis than
SLHCC does.
The distinct phenotypes exhibited by SLHCC and NHCC would
likely be attributable to differences in gene expression. Our
microarray analyses indicate that it is indeed the case. Among 8464
human genes examined, a total of 668 genes are differentially
expressed between SLHCC and NHCC. While further studies are
required to examine how those genes might contribute to the
pathology of HCC, the difference in gene expression may represent
the molecular basis underlying the distinct phenotypes exhibited
by NHCC and SLHCC.
Owing to its role in cytoskeletal reorganisation, in focal
adhesion contacts (Nobes and Hall, 1995; Kimura et al, 1996;
Leung et al, 1996) and in tumour invasion (Clark et al, 2000), RhoC
was chosen from the pool of 668 differentially expressed genes for
further analysis of the possibility that increased RhoC expression
might correlate with HCC metastasis. Three different approaches,
RT–PCR to measure mRNA levels, Western and immunohisto-
chemical staining to determine protein levels, were employed to
verify the expression of RhoC. Our data indicate that the
expression of RhoC was significantly higher in HCC tissues than
that in the corresponding PCLT. Furthermore, increased expres-
sion of RhoC in HCC seemed to correlate positively with poor cell
differentiation and with tumour vein invasion. It is well
documented that HCC often undergo dedifferentiation (from
well-differentiated to poorly differentiated) during multistep
tumour progression (Mise et al, 1998), and that some HCC
acquire metastatic potential during this progression, resulting in
vein invasion (Hui et al, 1999). Our results suggest that increased
expression of RhoC is closely associated with the later events in
liver carcinogenesis.
Our present study also showed that extrahepatic metastasis of
HCC expressed significantly higher RhoC levels than intrahepatic
HCC, and elevated expression of RhoC positively correlated with
vein invasion, and the number of tumour nodes. Similar
observations have been reported in other types of tumours. For
instance, overexpression of RhoC was found in metastatic lesions
of inflammatory breast cancer and pancreatic ductal adenocarci-
noma (Suwa et al, 1998; Fritz et al, 2002; Kleer et al, 2002), and
upregulation was associated with tumour progression in ovarian
carcinoma (Horiuchi et al, 2003). While the molecular mechanism
by which RhoC facilitates tumour metastasis remains to be
determined, it is possible that increased expression of RhoC could
result in: (1) disruption of cell polarity, which plays an important
role in the epithelial–mesenchymal transition observed in more
aggressive tumours (Zondag et al, 2000); (2) contribution to the
loss of adherens junctions (Braga et al, 2000); (3) increase motility
and ability to remould the extra-cellular matrix, which is required
for tumour cells to become locally invasive (Khanna et al, 2001);
and (4) increase in angiogenic factors that would result in
promotion of vascularisation in tumour and increase the like-
lihood of tumour cell entering the bloodstream (van Golen et al,
2000).
Our data suggest a possibility that RhoC expression could be
used as a potential prognostic marker for HCC patients. To test
this possibility, anti-RhoC immunohistochemical staining was
performed on 94 cases of HCC that included the 25 cases
mentioned above. Owing to the lower detection sensitivity of the
immunohistochemistry method, some of the 94 cases of HCC
showed negative staining of RhoC, despite the fact that RhoC
protein can be detected in all 25 cases of HCC with Western
blotting. Nevertheless, when we divided the total cases of HCC into
either a RhoC-positive or -negative group, the RhoC-negative HCC
patients in general had a better prognosis than the RhoC-positive
HCC patients. Together, our data strongly suggest that increased
RhoC expression in HCC correlates with a poor prognosis.
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